Is ruxolitinib tablets/ruxolitinib covered by medical insurance?

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib), as a highly selective JAK1/JAK2 inhibitor, plays an important role in the treatment of hematological tumors and myeloproliferative diseases. Since this type of disease often has a chronic and progressive course, patients need to take long-term medication, and the price of targeted drugs puts great financial pressure on families. Therefore, whether they are included in medical insurance has become the focus of widespread concern among patients and doctors.

At present, the original drug of ruxolitinib has been approved for marketing in China and is sold in the form of ruxolitinib phosphate tablets. More importantly, the drug has been included in the reimbursement scope of Category B in the National Medical Insurance List, which has greatly improved patients’ medication accessibility. After medical insurance reimbursement, the patient's out-of-pocket payment ratio has dropped significantly, reducing the financial burden and allowing more patients with medium- and high-risk myelofibrosis and polycythemia vera who are resistant or intolerant to hydroxyurea to receive long-term and standardized treatment.

Within the specific scope of medical insurance coverage, ruxolitinib is suitable for patient groups who have a clear diagnosis in the past and meet guideline recommendations. For example, patients with myelofibrosis are often accompanied by clinical manifestations such as significant spleen enlargement, general fatigue, and weight loss during the progression of the disease. Conventional drugs often have limited efficacy. Ruxolitinib can effectively improve spleen volume and clinical symptoms by acting on the JAK-STAT signaling pathway, thereby improving quality of life. For patients with polycythemia vera, ruxolitinib also provides a more targeted alternative when hydroxyurea cannot be continued. The intervention of medical insurance not only expands the population of drug users, but also promotes the popularization of this type of targeted drugs in clinical practice.

Although ruxolitinib has been included in medical insurance, specific reimbursement still needs to be combined with medical insurance policies, indication scope and local implementation rules. There may be differences in reimbursement ratios and payment ceilings in different regions. Patients can consult their medical institutions or medical insurance departments for specific policies before use.

Reference materials:https://www.jakavi.com/